Cite
HARVARD Citation
Girard, N. et al. (n.d.). 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study. Immuno-oncology technology. p. . [Online].